Mattia Galli/LinkedIn
Sep 11, 2025, 08:32
Rivaroxaban vs Apixaban in AFib and PAD – What the Data Say
Mattia Galli, Assistant Professor at Sapienza Università di Roma, Associate Editor of European Heart Journal, shared a post on X:
”Effectiveness and safety of rivaroxaban vs. apixaban in patients with atrial fibrillation and peripheral artery disease.”
Read more here.
Stay updated with Hemostasis Today.
-
Aug 22, 2026, 10:41Mike R.։ VTE Thrombectomy – Defining What Success Really Means
-
Aug 22, 2026, 10:28Steven Meier: What Happens During PRP Therapy?
-
Aug 22, 2026, 10:05Ralf Ludwig: When a Promising Biomarker Falls Short
-
Aug 22, 2026, 09:33Mary Cushman: What Causes PE to Happen in People with DVT?
-
Aug 22, 2026, 07:45Ziad Hijazi: Refining Risk Assessment in Atrial Fibrillation Without Oral Anticoagulation
-
Aug 22, 2026, 07:35Archil Jaliashvili: The Real Battle Is Not About Blood Volume — It Is About Oxygen
-
Aug 21, 2026, 21:58Toby Richards: WEHI Trial Solidifies IV Iron as Third-Trimester Standard
-
Aug 21, 2026, 21:51Mehak Trehan: From Reading the Chapter to Writing One
-
Aug 21, 2026, 21:38Ann Reilly: Navigating Postoperative vs. Acute Blood Loss Anemia – A CDI Case Study